Search Result

Results for "

6-Carboxy-X-rhodamine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (2) Bcl-2 Family (2) Caspase (1) DNA Stain (2) Fluorescent Dye (4) GLP Receptor (2) Insulin Receptor (2) Isotope-Labeled Compounds (2) p38 MAPK (2) α-synuclein (2)
By Research Areas:	Cancer (3) Metabolic Disease (2) Neurological Disease (2)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-D0053

6-ROX 6-Carboxy-X-rhodamine	Fluorescent Dye	Others
6-ROX is a selective fluorescent probe and potential inhibitor of COX-2. 6-ROX binds to the active site of COX-2 and inhibits its conversion of arachidonic acid into prostaglandins. 6-ROX is often used in the field of optical imaging related to tumors and inflammation, and helps detect diseased tissues with high expression of COX-2 .

HY-D0053A

6-ROX hydrochloride 6-Carboxy-X-rhodamine hydrochloride	Fluorescent Dye	Others
6-ROX (6-Carboxy-X-rhodamine) hydrochloride, a fluorescent marker of oligonucleotides, acts as a receptor coupled to 5-FAM and as a donor in FRET imaging. Excitation wavelength: 568 nm. Emission wavelength: 568 nm.

HY-D1086

6-Carboxy-X-rhodamine, succinimidyl ester 6-ROX, SE	DNA Stain	Others
6-Carboxy-X-rhodamine, succinimidyl ester (6-ROX, SE) is a fluorescent dye for oligonucleotide labeling and automated DNA sequencing .

HY-D0043

5(6)-ROX 1 Publications Verification 5(6)-Carboxy-X-rhodamine	DNA Stain	Others
5(6)-ROX (5(6)-Carboxy-X-rhodamine) is a nucleic acid fluorescent label which can be used as a reference dye for real-time polymerase chain reaction (Em/Ex = 605/585 nm) .

HY-P4403

Z-DEVD-R110 (Z-Asp-Glu-Val-Asp)₂-rhodamine 110	Fluorescent Dye Apoptosis Caspase	Others
Z-DEVD-R110 ((Z-Asp-Glu-Val-Asp)₂-Rhodamine 110) is a fluorogenic caspase-3/7 substrate. Z-DEVD-R110 can be used to detect apoptosis. Z-DEVD-R110 is a rhodamine derivative with two four–amino acid (DEVD) peptides linked to the fuorophore .

HY-P10322

Z-IETD-R110	Fluorescent Dye	Cancer
Z-IETD-R110 is a fluorescent substrate of caspases. Z-IETD-R110 acts as a substrate for caspase-8. When caspase-8 is activated, it can recognize and cut Z-IETD-R110, releasing fluorophore, which can be detected by fluorescence microscopy. Z-IETD-R110 can be used to study oxidative stress-induced apoptosis, particularly in pancreatic acinar cells .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Cat. No.	Product Name	Type

HY-D0053

6-ROX 6-Carboxy-X-rhodamine	Oligonucleotide Labeling
6-ROX is a selective fluorescent probe and potential inhibitor of COX-2. 6-ROX binds to the active site of COX-2 and inhibits its conversion of arachidonic acid into prostaglandins. 6-ROX is often used in the field of optical imaging related to tumors and inflammation, and helps detect diseased tissues with high expression of COX-2 .

HY-D1086

6-Carboxy-X-rhodamine, succinimidyl ester 6-ROX, SE	Fluorescent Dyes/Probes
6-Carboxy-X-rhodamine, succinimidyl ester (6-ROX, SE) is a fluorescent dye for oligonucleotide labeling and automated DNA sequencing .

HY-D0043

5(6)-ROX 1 Publications Verification 5(6)-Carboxy-X-rhodamine	Oligonucleotide Labeling
5(6)-ROX (5(6)-Carboxy-X-rhodamine) is a nucleic acid fluorescent label which can be used as a reference dye for real-time polymerase chain reaction (Em/Ex = 605/585 nm) .

Cat. No.	Product Name	Target	Research Area

HY-P4403

Z-DEVD-R110 (Z-Asp-Glu-Val-Asp)₂-rhodamine 110	Fluorescent Dye Apoptosis Caspase	Others
Z-DEVD-R110 ((Z-Asp-Glu-Val-Asp)₂-Rhodamine 110) is a fluorogenic caspase-3/7 substrate. Z-DEVD-R110 can be used to detect apoptosis. Z-DEVD-R110 is a rhodamine derivative with two four–amino acid (DEVD) peptides linked to the fuorophore .

HY-P10322

Z-IETD-R110	Fluorescent Dye	Cancer
Z-IETD-R110 is a fluorescent substrate of caspases. Z-IETD-R110 acts as a substrate for caspase-8. When caspase-8 is activated, it can recognize and cut Z-IETD-R110, releasing fluorophore, which can be detected by fluorescence microscopy. Z-IETD-R110 can be used to study oxidative stress-induced apoptosis, particularly in pancreatic acinar cells .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Cat. No.	Product Name	Chemical Structure

HY-114118S1

Semaglutide-d8 tetraTFA
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.